Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : The Obama - Clinton Disaster -- Ignore unavailable to you. Want to Upgrade?

To: Hope Praytochange who wrote (32726)	7/1/2010 11:45:16 PM
From: DuckTapeSunroof	Read Replies (1) \| Respond to of 103300

Talk about shooting themselves in the foot....

To: Hope Praytochange who wrote (32726)	7/2/2010 12:17:43 AM
From: DuckTapeSunroof	Read Replies (1) \| Respond to of 103300

German Chancellor Angela Merkel’s cabinet has approved legislation that will require drugmakers and insurers to negotiate prices of new drugs based on cost-effectiveness, PharmaTimes reports. However, the bill would also allow drugmakers to set unilateral prices if agreement with insurers is not reached after 15 months. The legislation must still be approved by the Bundestag, the lower house of parliament, which this month backed proposals to increase rebates paid to manufacturers on patented drugs but also set price limits, PharmaTimes notes, adding that the measures could go into effect by January and save about $2 billion next year. pharmatimes.com